The United States Trade Representative (USTR) has initiated a Section 301 investigation against Germany, alleging that its policies lead to persistent underpayment for innovative pharmaceutical products. This investigation, launched on June 18, 2026, claims that Germany's suppression of drug prices below fair market value compels American patients to bear a disproportionate share of global pharmaceutical research and development costs. The USTR will open a docket for public comments on June 25, 2026, with a deadline for submissions and requests to appear at a public hearing on August 10, 2026. A public hearing is scheduled for September 22, 2026.
This action follows previous communications from the USTR, including a May 2025 "Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation." The investigation will specifically examine how Germany's acts, policies, and practices depress pharmaceutical prices within its market. The USTR seeks to determine the extent to which these practices burden the US healthcare system and its consumers.
The investigation arises in the context of recent decisions by pharmaceutical giants Eli Lilly and Boehringer Ingelheim to cut planned investments in Germany. Both companies cited uncertainty and concerns over Germany's proposed healthcare reforms, which aim to reduce government healthcare spending and lower branded drug prices. Eli Lilly reduced its planned $2.7 billion investment by half, affecting a manufacturing facility in Alzey, and Boehringer Ingelheim cut its domestic spending by $1 billion from 2027 to 2030. These cuts highlight the industry's strong reaction to Germany's pricing policies, with Eli Lilly's CEO stating that Germany would become one of the least supportive European markets for the industry. Germany is now reportedly reconsidering some aspects of its proposed drug price reforms, moving from variable discounts to fixed reductions, in response to industry pushback.
While the specific Financial Times article about "Eli Lilly and Bayer hit out at Germany’s spending on new medicines" at the provided URL was not directly accessible, the USTR investigation and the reactions from Eli Lilly and Boehringer Ingelheim, as described in the available search results, strongly align with the sentiment and context of such a headline. The core issue revolves around Germany's healthcare spending on new medicines and the perception by pharmaceutical companies and the US government that these policies unfairly depress prices.
